Evans Terry L 4

What Happened
Terry L. Evans, Chief Commercial Officer of Fennec Pharmaceuticals (FENC), had 168 shares released from restriction on 2026-06-30. The Form 4 reports these 168 shares as an acquisition (award/release) at $0.00 (total reported value $0), reflecting the vesting/release of previously granted restricted stock.

Key Details

• Transaction date: 2026-06-30; Report filed: 2026-07-01 (Form 4 accession 0002043317-26-000008).
• Price: $0.00 per share; Total reported value: $0.
• Shares involved: 168 shares released from restriction.
• Footnote: Shares were released from restriction from an award originally granted 2025-03-28.
• Shares owned after transaction: not specified in this filing.
• Timeliness: Filing appears timely (filed the following day); not indicated as late.

Context
This was a vesting/release of previously awarded restricted shares (compensation), not an open-market purchase or sale. No immediate sale or cashless exercise is reported here; any future sale would appear in a separate Form 4. Vesting releases are common forms of executive compensation and are different from insider purchases or sales.